北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer
作者: Wang, Zhi-jie1,2; An, Tong-tong1; Mok, Tony4; Yang, Lu1; Bai, Hua1,2; Zhao, Jun1,2; Duan, Jian-chun1,2; Wu, Mei-na1,2; Wang, Yu-yan1,2; Li, Ping-ping1,3; Sun, Hong3; Yang, Ping5; Wang, Jie1,2
关键词: EGFR tyrosine kinase inhibitor ; Maintenance therapy ; Non-small-cell lung cancer
刊名: CHINESE JOURNAL OF CANCER RESEARCH
发表日期: 2011-06-01
DOI: 10.1007/s11670-011-0112-5
卷: 23, 期:2, 页:112-117
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: PHASE-III TRIAL ; FACTOR RECEPTOR MUTATIONS ; GEFITINIB ; GEMCITABINE ; ERLOTINIB ; BEVACIZUMAB ; CARBOPLATIN ; CISPLATIN ; PLACEBO ; TUMORS
英文摘要:

To analyze the outcomes of patients who received TKI immediately after the first-line without progression as maintenance treatment (immediate group) vs. those received delayed treatment upon disease progression as second-line therapy (delayed group).

The study included 159 no-small-cell lung cancer (NSCLC) patients who received gefitinib or erlotinib as maintenance treatment in the immediate group (85 patients) or as second-line therapy in the delayed group (74 patients). The primary end point was progression-free survival (PFS). EGFR mutation status was detected using denaturing high-performance liquid chromatography (DHPLC).

PFS was 17.3 and 16.4 months in the immediate and delayed groups, respectively (hazard ratio [HR], 0.99; 95% Confidence Interval [CI]: 0.69-1.42; P=0.947). In a subgroup analysis that included only patients with EGFR mutation, however, PFS was significantly longer in the immediate group than in the delayed group (HR, 0.48; 95% CI: 0.27-0.85; P=0.012). In patients with wild type EGFR, the risk for disease progression was comparable between the two groups (HR, 1.23; 95% CI: 0.61-2.51; P=0.564). No significant difference was demonstrated between the immediate and delayed group in terms of the overall survival (OS) (26.1 months vs. 21.6 months, respectively; HR=0.53; 95% CI: 0.27 to 1.06; P=0.072). There was also no difference in the incidence of adverse events between the two groups.

EGFR TKI maintenance improves PFS in patients with EGFR mutation. Prospectively designed clinical studies that compare TKI immediate vs. delayed treatment after first-line chemotherapy upon disease progression are needed.

语种: 英语
所属项目编号: 81025012 ; 30772472
项目资助者: China National Funds for Distinguished Young Scientists ; Capital Development Foundation
WOS记录号: WOS:000290804600005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/52025
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Gen Hosp Navy, Dept Oncol, Beijing, Peoples R China
2.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100871, Peoples R China
3.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Thorac Med Oncol, Beijing 100871, Peoples R China
4.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Integrat Med, Beijing 100871, Peoples R China
5.Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China

Recommended Citation:
Wang, Zhi-jie,An, Tong-tong,Mok, Tony,et al. Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer[J]. CHINESE JOURNAL OF CANCER RESEARCH,2011,23(2):112-117.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Wang, Zhi-jie]'s Articles
[An, Tong-tong]'s Articles
[Mok, Tony]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Wang, Zhi-jie]‘s Articles
[An, Tong-tong]‘s Articles
[Mok, Tony]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace